Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Session Coverage

Dr Secemsky
AMP 2022
Quality of Life Improvement After PVI: Insights From the LIBERTY 360 Study
08/19/2022
Written by Cynthia Laufenberg, MA Presented by Eric Secemsky, MD, MSc, FACC, FAHA, FSCAI, FSVM Thursday’s sessions kicked off with “Atherectomy: Controversial or Essential?” Included was a presentation by Eric Secemsky, MD, MSc, FACC,...
Written by Cynthia Laufenberg, MA Presented by Eric Secemsky, MD, MSc, FACC, FAHA, FSCAI, FSVM Thursday’s sessions kicked off with “Atherectomy: Controversial or Essential?” Included was a presentation by Eric Secemsky, MD, MSc, FACC,...
Written by Cynthia Laufenberg,...
08/19/2022
Vascular Disease Management
Dr. Ido Weinberg
AMP 2022
9-Month Data of the IN.PACT BTK Randomized Pilot Study: A Paclitaxel DCB vs Standard PTA for Infrapopliteal CTOs
08/18/2022
Written by Cynthia Laufenberg, MA Presented by Ido Weinberg, MD One of the presentations at Wednesday’s session, “The Role of Drug-Eluting Technologies in CLI,” was “9-Month Data of the IN.PACT BTK Randomized Pilot Study: A Paclitaxel...
Written by Cynthia Laufenberg, MA Presented by Ido Weinberg, MD One of the presentations at Wednesday’s session, “The Role of Drug-Eluting Technologies in CLI,” was “9-Month Data of the IN.PACT BTK Randomized Pilot Study: A Paclitaxel...
Written by Cynthia Laufenberg,...
08/18/2022
Vascular Disease Management
Abigail Mize
AMP 2022
Hemodynamic Assessment of the CLI Patient
08/18/2022
Written by Cynthia Laufenberg, MA Presented by Abigail Mize, BS, RDCS, RVT At Wednesday’s session, “What We All Need to Know About Wounds in the CLI Patient: Modern Core Wound Principles for the CLI Practitioner,” Abigail Mize, Clinical...
Written by Cynthia Laufenberg, MA Presented by Abigail Mize, BS, RDCS, RVT At Wednesday’s session, “What We All Need to Know About Wounds in the CLI Patient: Modern Core Wound Principles for the CLI Practitioner,” Abigail Mize, Clinical...
Written by Cynthia Laufenberg,...
08/18/2022
Vascular Disease Management
Dr. Anahita Dua
AMP 2022
Gender Disparities in CLI Patients
08/18/2022
Written by Cynthia Laufenberg, MA Presented by Anahita Dua, MD, FACS At Wednesday’s session “The Amputation Epidemic: Impact on Minority & Underserved Populations,” Dr. Anahita Dua of Massachusetts General Hospital/Harvard Medical...
Written by Cynthia Laufenberg, MA Presented by Anahita Dua, MD, FACS At Wednesday’s session “The Amputation Epidemic: Impact on Minority & Underserved Populations,” Dr. Anahita Dua of Massachusetts General Hospital/Harvard Medical...
Written by Cynthia Laufenberg,...
08/18/2022
Vascular Disease Management
Dr. Bryce
AMP 2022
Closing the Gaps in Racial Disparities in CLI Outcomes and Amputation Rates
08/18/2022
Written by Cynthia Laufenberg, MA Presented by Yolanda Bryce, MD, RVPI At the opening session on the first day of AMP 2022, “The Amputation Epidemic: Impact on Minority & Underserved Populations,” Dr. Yolanda Bryce of Memorial Sloan...
Written by Cynthia Laufenberg, MA Presented by Yolanda Bryce, MD, RVPI At the opening session on the first day of AMP 2022, “The Amputation Epidemic: Impact on Minority & Underserved Populations,” Dr. Yolanda Bryce of Memorial Sloan...
Written by Cynthia Laufenberg,...
08/18/2022
Vascular Disease Management
Scott REALITY
AMP 2021
Scott: 12-Month Results of the REALITY Study of Directional Atherectomy Alone and With Drug-Coated Balloons
08/13/2021
In a session devoted to atherectomy and its use in patients with critical limb ischemia (CLI), Eric C. Scott, MD (The Iowa Clinic, Des Moines, Iowa), shared the 12-month results of the REALITY study of directional atherectomy alone and with...
In a session devoted to atherectomy and its use in patients with critical limb ischemia (CLI), Eric C. Scott, MD (The Iowa Clinic, Des Moines, Iowa), shared the 12-month results of the REALITY study of directional atherectomy alone and with...
In a session devoted to...
08/13/2021
Vascular Disease Management
Practice Patterns and Outcomes Associated With Atherectomy Use for Peripheral Vascular Intervention
Reported by Debra L. Beck, MSc; Presented by Eric Secemsky, MD, MSc. Market analysis suggest that the peripheral atherectomy market in the US and globally is a healthy and growing one, s...
09/23/2020
PRELUDE-BTK Study Update: Serranator Balloon Catheter Feasibility Study
During a late-breaking clinical trial session at AMP 2020 Virtual, Michael Lichtenberg, MD, from the Arnsberg Vascular Clinic in Arnsberg, Germany, presented an update of the PRELUDE-BTK ...
09/23/2020
All CLI Patients Have Complex Lesions: Does Complex Mean the Same for All the Operators?
“I hope and I think that complex lesion means the same to all operators,” said Dr. Luis Mariano Palena, MD, director of endovascular surgery at Maria Cecilia Hospital in Cotignola, Italy....
09/23/2020
Acute Compartment Syndrome: Four First Steps to Diagnosis and Management
Acute compartment syndrome is an important complication of peripheral intervention and one that requires quick diagnosis and treatment, said Eric Scott, MD, at the start of his AMP 2020 V...
09/23/2020

Advertisement

Advertisement

Stay in the Know

Vascular Disease Management Newsletter

Advertisement

Advertisement

News

First Aid guidelines
AHA/American Red Cross: Updated First Aid Guidelines Enhance Care for Opioid Overdose, Bleeding, Other Emergencies
11/14/2024
These are the first major comprehensive updates to the first aid guidelines since 2010 and address shifts in how the public manages common and critical first aid emergencies.
These are the first major comprehensive updates to the first aid guidelines since 2010 and address shifts in how the public manages common and critical first aid emergencies.
These are the first major...
11/14/2024
Cath Lab Digest
Late-Breaking Trials
Final Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/06/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final round of Late-Breaking Clinical Trials presented at...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final round of Late-Breaking Clinical Trials presented at...
The VIVA Foundation, a...
11/06/2024
Vascular Disease Management
Late-Breaking Trials
Third Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/05/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the third of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the third of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a...
11/05/2024
Vascular Disease Management
Late-Breaking Trials
Second Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/04/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a...
11/04/2024
Vascular Disease Management
Late-Breaking Trials
First Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/04/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a...
11/04/2024
Vascular Disease Management
Image-Guided Therapy
Philips Enrolls First Patient in U.S. Clinical Trial for Innovative Integrated Single-Device to Treat Peripheral Artery Disease
11/04/2024
With a unique world-first ability to perform laser atherectomy and laser-based intravascular lithotripsy using a single device, Philips takes a major step forward in the treatment of peripheral artery disease (PAD) Cardiovascular...
With a unique world-first ability to perform laser atherectomy and laser-based intravascular lithotripsy using a single device, Philips takes a major step forward in the treatment of peripheral artery disease (PAD) Cardiovascular...
With a unique world-first...
11/04/2024
Vascular Disease Management
Pulmonary Embolism
Akura Medical Secures FDA Approval for US Pivotal Trial in Pulmonary Embolism
11/04/2024
QUADRA-PE study will evaluate the safety and effectiveness of the Katana™ Thrombectomy System LOS GATOS, Calif., Nov. 4, 2024 /PRNewswire/ -- Akura Medical, a Shifamed portfolio company focused on reshaping the...
QUADRA-PE study will evaluate the safety and effectiveness of the Katana™ Thrombectomy System LOS GATOS, Calif., Nov. 4, 2024 /PRNewswire/ -- Akura Medical, a Shifamed portfolio company focused on reshaping the...
QUADRA-PE study will evaluate...
11/04/2024
Vascular Disease Management
Peripheral Arterial Disease
FDA Grants R3 Vascular IDE Approval for ELITE-BTK Pivotal Trial of its MAGNITUDE® Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease
11/04/2024
MOUNTAIN VIEW, Calif. – November 4, 2024 – R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce...
MOUNTAIN VIEW, Calif. – November 4, 2024 – R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce...
MOUNTAIN VIEW, Calif. – November...
11/04/2024
Vascular Disease Management
Patient Awareness
Baby Boomers Beware: More Americans Than Ever Before Now at Higher Risk for Common Blood Vessel Diseases
10/31/2024
New survey reveals nearly one in three Americans at highest risk for blood vessel diseases and life-threatening complications report low awareness Society for Vascular Surgery launches the Highway to Health campaign to help people maintain...
New survey reveals nearly one in three Americans at highest risk for blood vessel diseases and life-threatening complications report low awareness Society for Vascular Surgery launches the Highway to Health campaign to help people maintain...
New survey reveals nearly one in...
10/31/2024
Vascular Disease Management
DCB
SIRONA Trial @TCT – First Head-to-Head Comparison of Sirolimus Versus Paclitaxel DCBs in the Treatment of PAD: Sirolimus-Coated Balloons Yield Similar Results to Paclitaxel-Coated Balloons in the Femoropopliteal Artery
10/30/2024
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...
Data from the prospective,...
10/30/2024
Cath Lab Digest

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement